CytoReason to license IBD disease model to Sanofi

CytoReason announced an expansion of its collaboration with Sanofi. The multiyear collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease, to identify patient subtypes and pair them with IBD targets. In 2021, Cytoreason announced the initiation of a project with Sanofi utilizing cell-centered models to suggest mechanistic insights for asthma endotypes. Under the terms of the expanded agreement, Sanofi will pay CytoReason an undisclosed multimillion dollar amount. Sanofi has previously applied Cytoreason’s cell-centered model to better understand asthma patient subtypes